Uncategorized
Alcon launches ocriplasmin in UK market
Alcon has launched ocriplasmin for the treatment of vitreomacular traction in the United Kingdom, its first market in Europe, according to a news release from ThromboGenics.Alcon, which has the rights to commercialize Jetrea (ocriplasmin, ThromboGenics) outside the United States, paid ThromboGenics €45 million when the European Commission approved ocriplasmin to treat vitreomacular traction, including when associated with a macular hole of 400 µm or less in diameter, earlier this year.